Intervention Review

You have free access to this content

Anti-vascular endothelial growth factor for neovascular glaucoma

  1. Arathi Simha1,*,
  2. Andrew Braganza1,
  3. Lekha Abraham1,
  4. Prasanna Samuel2,
  5. Kristina Lindsley3

Editorial Group: Cochrane Eyes and Vision Group

Published Online: 2 OCT 2013

Assessed as up-to-date: 11 JAN 2013

DOI: 10.1002/14651858.CD007920.pub2


How to Cite

Simha A, Braganza A, Abraham L, Samuel P, Lindsley K. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD007920. DOI: 10.1002/14651858.CD007920.pub2.

Author Information

  1. 1

    Christian Medical College, Department of Ophthalmology, Vellore, India

  2. 2

    Christian Medical College, Department of Biostatistics, Vellore, Tamil Nadu, India

  3. 3

    Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Baltimore, Maryland, USA

*Arathi Simha, Department of Ophthalmology, Christian Medical College, Vellore, 632001, India. arathisimha@rediffmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 2 OCT 2013

SEARCH

References

References to studies excluded from this review

  1. References to studies excluded from this review
  2. References to studies awaiting assessment
  3. Additional references
  4. References to other published versions of this review
Caujolle 2012 {published data only}
  • Caujolle JP, Maschi C, Freton A, Pages G, Gastaud P. Treatment of neovascular glaucoma after proton therapy for uveal melanomas with ranibizumab injection: preliminary results. Ophthalmic Research 2012; Vol. 47, issue 2:57-60.
Costagliola 2008 {published data only}
  • Costagliola C, Cipollone U, Rinaldi M, della Corte M, Semeraro F, Romano MR. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up. British Journal of Clinical Pharmacology 2008;66(5):667-73.
Eid 2009 {published and unpublished data}
  • Eid T, Radwan A, el-Manawy W, el-Hawary I. Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy. Canadian Journal of Ophthalmology 2009;44(4):451-6.
  • Eid T, Radwan A, el-Menawy W, el-Hawary I. Outcome of intravitreal bevacizumab (Avastin) followed by aqueous shunting surgery for management of intractable neovascular glaucoma. American Academy of Ophthalmology. 2008:219.
Gupta 2009 {published data only}
  • Georgalas I, Koutsandrea C, Papaconstantinou D, Petrou P, Ladas I. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. European Journal of Ophthalmology 2010; Vol. 20, issue 1:251.
  • Gupta V, Jha R, Rao A, Kong G, Sihota R. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. European Journal of Ophthalmology 2009;19(3):435-41.
Jonas 2010 {published data only}
  • Jonas JB, Golubkina L, Libondi T, Rensch F. Intravitreal bevacizumab for neovascular glaucoma. Acta Opthalmologica 2010; Vol. 88, issue 2:e22-3.
Miki 2011 {published data only}
  • Miki A, Oshima Y, Otori Y, Matsushita K, Nishida K. One-year results of intravitreal bevacizumab as an adjunct to trabeculectomy for neovascular glaucoma in eyes with previous vitrectomy. Eye 2011; Vol. 25, issue 5:658-9.
NCT01711879 {unpublished data only}
  • NCT01711879. Use of intravitreal aflibercept injection for neovascular glaucoma. clinicaltrials.gov/ct2/show/NCT01711879 (accessed 21 August 2013).
Sedghipour 2011 {published data only}
  • Sedghipour MR, Mostafaei A, Taghavi Y. Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma. Clinical Ophthalmology 2011; Vol. 5, issue 1:797-800.
Wittstrom 2012 {published data only}
  • Wittstrom E, Holmberg H, Hvarfner C, Andreasson S. Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab. European Journal of Ophthalmology 2012;22(4):563-74.
Yazdani 2009 {published data only}

References to studies awaiting assessment

  1. References to studies excluded from this review
  2. References to studies awaiting assessment
  3. Additional references
  4. References to other published versions of this review
Arcieri 2010 {unpublished data only}
  • Arcieri ES, Secches DJL, Paula JS, Barella KA, Arcieri RS, Jorge R, et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed Glaucoma Valve implantation - preliminary report. ARVO. 2010:627/A471.
Chakrabarti 2008 {unpublished data only}
  • Chakrabarti M, Chakrabarti A, Stephen V, John SR. Efficacy of combining intravitreal bevacizumab monotherapy with panretinal photocoagulation in early stages of neovascular glaucoma. American Academy of Ophthalmology. 2008:182.
NCT01128699 {unpublished data only}
  • NCT01128699. Ahmed valve glaucoma implant with adjunctive subconjunctival bevacizumab in refractory glaucoma. clinicaltrials.gov/ct2/show/NCT01128699 (accessed 20 August 2013).

Additional references

  1. References to studies excluded from this review
  2. References to studies awaiting assessment
  3. Additional references
  4. References to other published versions of this review
Aiello 1994
  • Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine 1994;331(22):1480-7.
Andreoli 2007
Assaad 1999
  • Assaad MH, Baerveldt G, Rockwood EJ. Glaucoma drainage devices: pros and cons. Current Opinion in Ophthalmology 1999;10(2):147-53.
Avery 2006
Blankenship 1988
Bloom 1997
  • Bloom PA, Tsai JC, Sharma K, Miller MH, Rice NS, Hitchings RA, et al. "Cyclodiode". Trans-scleral diode laser cyclophotocoagulation in the treatment of advanced refractory glaucoma. Ophthalmology 1997;104(9):1508-19.
Boyer 2009
  • Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116(9):1731-9.
Brown 2006
  • Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine 2006;355(14):1432-44.
Chang 2007
  • Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology 2007;125(11):1460-9.
Deeks 2011
  • Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Delgado 2003
  • Delgado MF, Dickens CJ, Iwach AG, Novack GD, Nychka DS, Wong PC, et al. Long-term results of noncontact neodymium:yttrium-aluminum-garnet cyclophotocoagulation in neovascular glaucoma. Ophthalmology 2003;110(5):895-9.
Doft 1984
Ehlers 2008
  • Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 2008;28(5):696-702.
Feibel 1972
Gandhi 2008
Gheith 2007
Grisanti 2006
Grover 2009
  • Grover S, Gupta S, Sharma R, Brar VS, Chalam KV. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. British Journal of Ophthalmology 2009; Vol. 93, issue 2:273-4.
Hayreh 1990
  • Hayreh SS, Klugman MR, Podhajsky P, Servais GE, Perkins ES. Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10-year prospective study. Graefe's Archive for Clinical and Experimental Ophthalmology 1990;228(4):281-96.
Hayreh 2003
Higgins 2011a
  • Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Higgins 2011b
  • Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Iliev 2006
Katz 1995
  • Katz GJ, Higginbotham EJ, Lichter PR, Skuta GL, Musch DC, Bergstrom TJ, et al. Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. Ophthalmology 1995;102(9):1263-9.
Kitnarong 2008
Kiuchi 2006
  • Kiuchi Y, Nakae K, Saito Y, Ito S, Ito N. Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma. Graefe's Archive for Clinical and Experimental Ophthalmology 2006;244(12):1627-32.
Kotecha 2011
  • Kotecha A, Spratt A, Ogunbowale L, dell’Omo R, Kulkarni A, Bunce C, Franks WA. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series. Archives of Ophthalmology 2011;129(2):145-50.
Kovacic 2004
  • Kovacic Z, Ivanisevic M, Rogosic V, Plavec A, Karelovic D. Cyclocryocoagulation in treatment of neovascular glaucoma [Ciklokriokoagulacija u lijecenju neovaskularnoga glaukoma]. Lijecnicki Vjesnik 2004;126(9-10):240-2.
Lalwani 2009
  • Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. American Journal of Ophthalmology 2009;148(1):43-58.
Martínez-Carpio 2008
  • Martínez-Carpio PA, Bonafonte-Márquez E, Heredia-García CD, Bonafonte-Royo S. Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review [Eficacia y seguridad de la inyección intravítrea de bevacizumab en el tratamiento del glaucoma neovascular: revisión sistemática]. Archivos de la Socidad Espanola de Oftalmologia 2008;83(10):579-88.
Meyer 2008
  • Meyer CF, Eter N, Holz FG. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN trial (abstract). Investigative Ophthalmology and Visual Science. 2008:E-abstract 273.
Minckler 2006
NCT00406471
  • NCT00406471. Rubeosis anti-VEGF (RAVE) trial for ischemic central retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT00406471 (accessed 9 November 2012).
Ohnishi 1994
Oshima 2006
  • Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. American Journal of Ophthalmology 2006;142(1):155-8.
Pagenstecher 1871
  • Pagenstecher M. Contribution to the teachings of hemorrhagic glaucoma [Beitrage zur Lehre vom hämorrhagischen Glaucom]. Graefe's Archive for Clinical and Experimental Ophthalmology 1871;17:98-130.
Review Manager 2012 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Rogell 1983
Sone 1996
  • Sone H, Okuda Y, Kawakami Y, Hanatani M, Suzuki H, Kozawa T, et al. Vascular endothelial growth factor level in aqueous humor of diabetic patients with rubeotic glaucoma is markedly elevated. Diabetes Care 1996;19(11):1306-7.
Tripathi 1998
  • Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 1998;105(2):232-7.
Tsai 1995
  • Tsai JC, Feuer WJ, Parrish RK 2nd, Grajewski AL. 5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study. Ophthalmology 1995;102(6):887-92.
Tsai 2008
  • Tsai JT, Wand M. Chapter 213: Neovascular Glaucoma. In: Alm A, Grosskreutz C editor(s). Albert and Jakobiec's Principles and Practice of Ophthalmology. 3rd Edition. Vol. 2, Canada: Saunders Elsevier, 2008:2689.
Vasudev 2009
VISION 2006
  • VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113(6):992-1001.
Wakabayashi 2008
  • Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008;115(9):1571-80.
Wilkins 2005
Wormald 2001
Yalvac 2007
Yazdani 2007

References to other published versions of this review

  1. References to studies excluded from this review
  2. References to studies awaiting assessment
  3. Additional references
  4. References to other published versions of this review
Simha 2009